Background and Objectives: Our objective was to identify differentially expressed genes involved in the pathogenesis of glioblastoma multiforme (GBM). Methods: Screening of arrayed human fetal brain and human postnatal brain cDNA libraries was performed by differential hybridization with glioblastoma multiforme and human normal brain cDNAs. Results: Repeated differential hybridization of more than 100 cDNA clones selected by primary screening and analysis of RNA from adult normal brain and glial tumors showed 16 nucleotide sequences differentially expressed between normal brain and brain tumors. Among others, decreased content in astrocytic tumors was determined for TSC-22 mRNA corresponding to cDNA in the ICRFp507J1041 clone from human fetal brain cDNA library. Northern blot hybridization of RNA from different human brain tumors showed very low amounts of TSC-22 mRNA in most investigated samples of GBM, anaplastic astrocytoma, and some other tumors. Complete lack of expression of TSC-22 occurred in one sample of anaplastic astrocytoma, as well as in meningioma, brain sarcoma, sarcomatous meningioma, and oligodendroglioma. The differential expression of TSC-22 gene was confirmed by semiquantitative RT-PCR in 15 samples of astrocytomas WHO grade II-IV and three samples of normal brain. Conclusions: Significantly decreased levels of TSC-22 mRNA in human brain and salivary gland tumors and antiproliferative role of TSC-22 strongly suggest a tumor suppressor role for TSC-22.
INTRODUCTION
The current picture of the molecular basis of human brain tumors presents a complex interplay between multiple genetic events involving nonrandom chromosomal anomalies, activation of protooncogenes, inactivation of tumor suppressor genes, and the aberrant expression of growth factors and their receptors. Epidermal growth factor receptor (EGFR), as well as platelet-derived growth factor (PDGF) and its receptors, have been characterized as contributing oncogenes. Several investigative groups have provided cytogenetic and molecular genetic evidence for the existence of unidentified putative tumor suppressor genes on chromosomal arms 1p, 9p, 10q, 11p, 13q, 17p, 19q, and 22q, in addition to known tumor suppressor genes [1] [2] [3] [4] [5] [6] [7] .
However, present knowledge recognizes only a fraction of the biological mechanisms assumed to initiate and promote brain tumor formation. The candidate gene approach, correlating common genetic alterations found in human brain tumors with outcome or response to treatment, has yielded contradictory results. A more comprehensive approach is to include gene expression in the analysis in order not only to concentrate on structural alterations, but also to encompass regulatory differences. Identification and characterization of novel molecular markers or genes either induced or repressed in human brain tumors will contribute to understanding the mechanisms of tumor initiation and progression. Better knowledge of such mechanisms is likely to improve diagnostic and prognostic evaluation, and is necessary to define biological targets for the design of comprehensive therapeutic approaches. Predictive markers would be extremely helpful in identifying patients who would benefit from specific treatments.
In this work, the TSC-22 gene (transforming growth factor-b [TGF-b1]-stimulated clone 22), originally identified as a primary response gene [8] , was found to have a significantly decreased level of the expression in some human brain tumors, as compared with that in normal brain. The present work describes the results in accordance with previously published data, indicating a potential tumor suppressor role of the TSC-22 gene.
MATERIALS AND METHODS

Human Tissues and cDNA Libraries
Brain tumor and normal tissues were procured from tumor tissue bank maintained by the Romodanov Institute of Neurosurgery, Kiev, Ukraine. Of 27 tumors used in this work, 23 were primary tumors, and 4 were recurrent tumors. One patient with a primary tumor received chemotherapy before surgical excision. Surgical specimens of human fetal brain were supplied by Center of Embryonic Tissues, Kiev. High-density cDNA filter arrays of human fetal and infant brain cDNA libraries came from The Resource Center/Primary Database (RZPD) of the German Human Genome Project (Max Planck Institute for Molecular Genetics, Berlin and Deutsches Krebsforschungszentrum, Heidelberg).
Differential Hybridization of cDNA Libraries
Differential hybridization of 32 P-labeled human glioblastoma and normal brain cDNAs to gridded human brain cDNA libraries was performed as described in our previous articles [9] [10] [11] . Total cDNA probes for differential hybridization were synthesized on the total RNAs, isolated from surgical specimens of human normal brain and primary astrocytic tumors: glioblastoma multiforme (GBM) and anaplastic astrocytoma. The conditions of oligo(dT)-primed cDNA synthesis were as described in standard procedure [12] , but the concentration of dCTP was reduced to 25 mM, and 150-200 mCi of [a-32 P]dCTP was added to the reaction to obtain cDNA probes with high specific activity. cDNA filter arrays were consequentially hybridized with tumor and normal brain cDNA probes and the coordinates of cDNA clones with altered hybridization signals between tumor and control cDNAs were determined on the gridded arrays. The clones were requested from RZPD (http:// www.rzpd.de); repeated differential hybridization of these clones was carried out.
RNA Isolation
Total RNA was isolated from liquid nitrogen-frozen surgical specimens of human brain tumors and normal tissues, as well as from samples of normal fetal human brain by acid guanidinium thyiocyanate-phenol-chlorophorm extraction [13] . (Surgical specimens of histologically normal brain tissue adjacent to tumor were used as a source for normal adult human brain RNA.)
Northern Blot Analysis
Total RNA (20 mg per lane) was separated electrophoretically in 1.5% agarose gel containing 2.2 M formaldehyde and was then transferred to a Hybond-N nylon membrane (Amersham Pharmacia Biotech). The membrane was hybridized with a 32 P-labeled human TSC-22 cDNA probe (10 6 cpm/ml) in 50% formamide; 5 Â SSC; 5 Â Denhardt's solution; 0.1% sodium dodecyl sulfate (SDS), and 100 mg/ml salmon sperm DNA at 428C overnight. Extensive washing was performed: twice with 2 Â SSC, 0.1% SDS for 15 min at room temperature; once with 2 Â saline sodium citrate (SSC), 0.1% SDS for 30 min at 658C; and finally with 0.2 Â SSC, 0.1% SDS for 30 min at 658C. Subsequently, the membrane was exposed to radiographic film with an intensifying screen at À708C. The membrane was rehybridized sequentially with a 32 P-labeled human b-actin cDNA probe as a control of gel loading. Densitometric analysis of signals was performed by Scion Image 1.62c program.
Southern Blot Analysis
Genomic DNA from human astrocytic tumors and from blood samples of tumor patients and unrelated individuals was isolated by phenol/chloroform extraction [12] , digested with HindIII endonuclease, separated by electrophoresis in 0.6% agarose gel in 1 Â TBE buffer, and transferred onto a Hybond-N nylon membrane (Amersham Pharmacia Biotech). The membrane was hybridized with a 32 P-labeled human TSC-22 cDNA (10 6 cpm/ml) in 50% formamide; 5 Â SSC; 5 Â Denhardt's solution; 0.1% SDS and 100 mg/ml salmon sperm DNA at 428C overnight. Washing conditions: twice with 2 Â SSC, 0.1% SDS for 30 min at room temperature; once with 2 Â SSC, 0.1% SDS for 30 min at 658C; and finally with 0.2 Â SSC, 0.1% SDS for 30 min at 658C. The filter was exposed to radiographic film with an intensifying screen at À708C.
Semiquantitative RT-PCR
Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) with TSC-22-specific primers was performed on normal brain and brain tumor RNA samples as described by Rae et al. [14] . Equal amounts of total cellular RNA (10 mg each) were reverse transcribed into cDNA with an oligo(dT) primer. In a 20-ml reaction, PCR was performed with cDNA synthesized from 0.5 mg of total RNA, 2 U Taq-polymerase, 1 Â PCR buffer, 0.2 mM dNTPs, and 1mM TSC-22-specific primers. Thermal cycling parameters were 948C for 30 s, 568C for 1 min, and 728C for 1 min for 30 cycles, followed by a further 7 min at 728C. The number of cycles was then decreased until the PCR product amplification rate was in the linear phase (27 cycles). Amplified products were electrophoresed in a 2% agarose gel and transferred to a nylon membrane. The membrane was subsequently hybridized with a 32 P-labeled TSC-22 cDNA probe (10 6 cpm/ml) in 50% formamide to detect very low quantities of TSC-22 mRNA in some tumor samples.
Nucleotide Sequence Analysis
Nucleotide sequences of cDNA inserts were determined according to the Sanger method [15] . The GenBank and EMBL databases were searched for overall nucleic acid homologies by the BLAST program via the Internet.
RESULTS
Identification of the Genes Differentially Expressed
Between Normal Brain and Brain Tumors
As with subtractive hybridization techniques [16] , differential hybridization is advantageous in that it does not require a priori sequence information, but it is unique in that both commonly and specifically expressed mRNAs in multiple tissues or cell samples can be compared simultaneously. Thus, in the same experiment, genes expressed only in normal tissues (e.g., tumor suppressor genes), as well as genes that are tumor specific (e.g., tumor markers, activated oncogenes), can be identified [17] .
Differential hybridization of arrayed human fetal brain and human postnatal brain cDNA libraries with total cDNA probes of GBM and normal adult brain showed more than 100 cDNA clones with differences in the intensity of hybridization. Repeated differential hybridization of cDNA clones, selected by primary screening, and nucleotide sequence analysis of cDNA inserts allowed us to identify 16 nucleotide sequences whose expression has been changed by 3-10-fold (for several cases, by more than 10-fold) in tumor cells. The information about these sequences is shown in Table I . The potential tumor-specific expression of isolated nucleotide sequences was verified by Northern blotting, using membranes with total RNA from brain tumors and control tissues. The total length and splice patterns of transcripts in normal human tissues and in astrocytomas of different malignancy grades were evaluated. Because of the problem presented by heterogeneous expression among individual tumors and among normal brain samples, different normal brain samples and astrocytoma tissues were subjected to comparative analysis.
TSC-22 mRNA was identified among the sequences with decreased content in the GBM. The nucleotide sequence of TSC-22 cDNA from human fetal brain cDNA clone ICRFp507J1041 is shown in Figure 1 (found under Accession No. AJ222700 in the databases). The nucleotide sequence of ICRFp507J1041 cDNA is identical to previously published TSC-22 cDNA nucleotide sequence [18, 19] but due to the alternative processing of the 3 0 -untranslated region the ICRFp507J1041 cDNA is two nucleotides shorter than the published TSC-22 cDNA. The heterogeneity of polyadenylation sites generated under the influence of a single polyadenylation signal was described by us previously for transcripts from three different genes in human fetal liver [20] .
Decreased Expression of TSC-22 Gene in Brain Tumors
Northern blot hybridization was carried out in order to examine the level and size of the TSC-22 gene transcript in individual human brain tumors (Fig. 2) . Four different samples of histologically normal adult brain, adjacent to the tumor and ablated due to necessity in the course of surgery, were used as a source of RNA for comparison of gene expression in normal brain. The radiolabeled TSC-22 cDNA hybridized to a major band of RNA of $1.8-kb size in normal tissues, e.g., heart and kidney (lanes 1 and 2) and adult normal brain (lanes 3-6) . However, amounts of the 1.8-kb mRNA were varied in the tumor tissues tested. Comparison of the hybridization signals with the TSC-22 cDNA probe clearly showed a significant decrease in TSC-22 mRNA contents in three of four GBM samples (lanes 8-10) . There was also a decreased level of the TSC-22 mRNA in the fourth GBM (lane 7). A very low level of TSC-22 mRNA was detected in three of five anaplastic astrocytomas (lanes 11, 14, 18 (Fig. 3) .
TSC-22 Gene Locus Does Not Have Deletions in Astrocytic Tumors
Southern blot hybridization of genomic DNA from astrocytomas of different malignancy grades and from blood samples of tumor patients and unrelated individuals was performed to examine possible deletions at the TSC-22 gene locus. HindIII-digested DNA was hybridized to a 32 P-labeled fragment of ICRFp507J1041 cDNA, synthesized by PCR, using primers pr1 and pr2 (positions of the primers are indicated in Fig. 1 ). This analysis did not show differences in the hybridization pictures of tumor DNA (Fig. 4) 
DISCUSSION
In the present study, we have identified the TSC-22 gene-one of the genes characterized by differential hybridization as differentially expressed between normal human brain and human brain tumors. We found that expression of this gene was significantly decreased in astrocytomas of different malignancy grades and in some other types of brain tumors.
The TSC-22 gene belongs to the family of early response genes and was originally isolated from mouse osteoblastoma cDNA library as a gene that was stimulated by transforming growth factor-b1 (TGF b1-stimulated clone 22) [8] . Its expression grows rapidly in response to cell treatment by bacterial lipopolysaccharides (LPS), some cytokines (TGF-b1, tumor necrosis factor-a [TNF-a], and interferon-g [IFN-g]) [19] , and other inductors (dexamethasone, cholera toxin, and phorbol 12-myristate 13-acetate [PMA]) [8] . TSC-22 was shown to be one of the target genes for progesterone [21] . Induction by progesterone suggests the presence of the progesterone response element in the TSC-22 gene promoter. The growth of the expression of the TSC-22 gene in the response to dexamethasone, a synthetic activator of the glucocorticoid receptor [8] , supports this suggestion. TSC-22 contains a leucine zipper motif. It has been hypothesized as a transcription factor [8] , although it does not contain a classic DNA-binding domain such as those in the bZip or bHLH-Zip families. TSC-22 was determined to be the transcription regulator of the C-type natriuretic peptide gene, interacting with GC-rich elements of its promoter [19] . Recent studies showed transcription repressor activity of TSC-22, which can form homodimers via its leucine zipper domain [22] . It is possible that TSC-22 may form heterodimers with basic leucine zipper transcription factors and that it may repress classical transcription activators as a dominant negative regulator, such as helix-loop-helix proteins Id1-Id4 [23] .
Decreased content, and even complete absence, of TSC-22 mRNA were also found in benign and malignant human salivary gland tumors, as compared with that in the normal salivary gland [24] . In contrast, TSC-22 displayed a negative regulatory effect on cell proliferation. The investigation of apoptotic cell death mechanism in the human gastric carcinoma cell line HSC-39 after treatment with TGF-b1 showed that TSC-22 can play the role of the mediator of TGF-b1 signaling pathway to apoptosis [25] . HSC-39 cells transfected with a TSC-22-expressing vector showed a significant decrease in cell viability and elicited apoptotic cell death through the activation of CPP32-like protease because the synthetic peptide inhibitor, specific to CPP32-type protease, protected the cells against death. Treatment of human salivary gland cancer cell line TYS under quiescent conditions by antisense oligonucleotide against TSC-22 mRNA stimulated the growth of TYS cells; however, under growing conditions, the antisense oligonucleotide did not affect cell growth [26] . Furthermore, the antiproliferative effect of anticancer drug vesnarinone was suppressed by the antisense oligonucleotide. These results also indicate that TSC-22 may be a negative regulator of cell growth and that it may play an important role in the antiproliferative effect of vesnarinone. Upregulation of the TSC-22 protein affected neither in vitro nor in vivo growth of TYS cells, but downregulation of TSC-22 markedly enhanced their growth in vitro and in vivo [24] .
The TSC-22 gene was mapped to chromosome 13 at position q14 [18] . The location of this gene on the chromosome 13 may be determined more precisely by the NCBI Map Viewer. The TSC-22 gene has been localized in the 13q13.2-13q13.3 region. The loss of the chromosome arm 13q occurs in up to 50% of human astrocytomas, suggesting the presence of astrocytoma tumor suppressor gene(s) at that location [27] [28] [29] [30] . Loss of heterozygosity (LOH) at the retinoblastoma (Rb) susceptibility gene locus, located on 13q14, was detected in 30% of high-grade astrocytomas, but was not detected in low-grade gliomas [27] . These results indicate that the Rb gene locus is targeted by the deletions in 13q, but they also suggest the possibility of the presence of other astrocytoma suppressor gene(s) in this regionand TSC-22 gene may be one of them. We performed Southern blot hybridization of genomic DNA from astrocytomas of different malignancy grades and from blood samples of tumor patients and unrelated healthy individuals, to examine possible deletions at the TSC-22 gene locus in astrocytic gliomas. However, Southern blot analysis did not demonstrate the differences in hybridization patterns of tumor and nontumor DNA. It may be concluded that the repression of TSC-22 gene activity in tumor cells may be caused by changes in its regulation.
Thus, the significantly decreased content of TSC-22 mRNA in human brain and salivary gland tumors and the negative role of TSC-22 protein in cell proliferation suggest the possible tumor suppressor role of this gene.
Recent studies showed that the constructions expressing TSC-22 may be useful in the chemotherapy of tumors. Overexpression of TSC-22 markedly enhanced chemosensitivity of human salivary gland cancer cells in vitro and in vivo via 5-fluorouracil-induced apoptosis [31, 32] .
